Pipeline

World leading manufacturer of recombinant human albumin

  • Contact
  • Albumin
    • Albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® products
    • Compliance services
    • Innovation services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • Covid-19
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog
Albumedix Partnering Pipeline
  • R&D collaborations
  • Pipeline

Partnered Pipeline

Albumedix’ albumin-based technologies are both clinically and commercially validated in a number of albumin-enabled pharmaceutical programs by partners. These programs include all from preclinical candidates to marketed products spanning a wide range of therapeutic indications. Together these programs and partnerships demonstrate the value and applicability of Albumedix’ recombinant human albumin products and technologies.

Full pipeline

Click on picture to view our full partnered pipeline

Merck partner showcase

Recombumin® is used in the manufacture of Merck & Co’s M-M-R® II and ProQuad® childhood vaccines

The vaccines are used in immunization against measles, mumps, rubella, and varicella virus infections in children 12 months through 12 years of age.

Since Recombumin was introduced in the M-M-R® II vaccine in 2006 more than >200 million doses have been administered in children worldwide.

CSL Behring partner showcase

Veltis® is used in CSL Behrings IDELVION®

Hemophilia B, is a genetic disorder caused by missing or defective factor IX. IDELVION® is recombinant factor IX replacement therapy.

Veltis® technology delivers the extended half-life to factor IX enabling a reduced frequency of injections; Idelvion is the only Hemophilia B Therapy with up to 14-day dosing intervals. Patients are able to maintain factor IX activity levels over a longer period of time, allowing greater freedom from frequent infusions.

You are always welcome to contact us to learn more about Albumedix' products and technologies 

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven company and recognized leader of best-in-class albumin-enabled solutions. Established in the UK in 1984, with a mission to empower excellence, Albumedix has supported its life-science partners to deliver hundreds of million safe doses of clinical and marketed therapeutics, globally. Albumedix’ solutions include the world’s only USP-NF compliant recombinant human albumin (Recombumin®), client-centric development and compliance services and drug-enhancing technologies (Veltis®). By always striving for more and collaboratively challenging status quo, Albumedix enables the development and commercialisation of advanced therapies and next-generation biopharmaceuticals to the benefit of people worldwide.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US

  • Albumin
    • Albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® products
    • Compliance services
    • Innovation services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • Covid-19
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

We use cookies on our website to improve the website and your experience.

Read more